PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34506778-5	2021	RESULTS: Sirt1-/- ventricles showed prolonged action potential duration at 90% repolarization and increased contractile force after treatment with ITI-214.	ITI-214	147-154	sirtuin 1	Mus musculus	9-14
34506778-7	2021	ITI-214 treatment decreased the rates and shortened the durations of burst firing in Sirt1-/- mice.	ITI-214	0-7	sirtuin 1	Mus musculus	85-90
34506778-8	2021	Sirt1-/- cardiomyocytes showed reduced Ca2+ transient amplitudes and sarcoplasmic reticulum (SR) Ca2+ stores compared to those in control cardiac myocytes, which was reversed after ITI-214 treatment.	ITI-214	181-188	sirtuin 1	Mus musculus	0-5
34506778-11	2021	Increased levels of reactive oxygen species in Sirt1-/- cardiomyocytes compared to those in controls were reduced after ITI-214 treatment.	ITI-214	120-127	sirtuin 1	Mus musculus	47-52
35173613-11	2021	Further, chronic lenrispodun treatment decreased TNF-alpha and IL-10 plasma levels while the elevated level of IL-6 in SMC-KO mice remained unchanged after treatment.	ITI-214	17-28	tumor necrosis factor	Mus musculus	49-58
35173613-11	2021	Further, chronic lenrispodun treatment decreased TNF-alpha and IL-10 plasma levels while the elevated level of IL-6 in SMC-KO mice remained unchanged after treatment.	ITI-214	17-28	interleukin 10	Mus musculus	63-68
35173613-11	2021	Further, chronic lenrispodun treatment decreased TNF-alpha and IL-10 plasma levels while the elevated level of IL-6 in SMC-KO mice remained unchanged after treatment.	ITI-214	17-28	interleukin 6	Mus musculus	111-115
31770590-6	2020	Functionally, ITI-214 inhibited ADP-induced migration of BV2 cells through a P2Y12-receptor-dependent pathway, possibly due to increases in the extent of cAMP and VASP phosphorylation downstream of receptor activation.	ITI-214	14-21	vasodilator-stimulated phosphoprotein	Mus musculus	163-167